Ligand Pharmaceuticals (LGND) Net Cash Flow (2010 - 2026)

Ligand Pharmaceuticals has disclosed Net Cash Flow across 17 years of filings, most recently posting -$59.8 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$59.8 million, down 136.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.8 million (up 3538.0% YoY), and the FY2025 annual result was $100.3 million, up 98.44% from the prior year.
• Net Cash Flow came in at -$59.8 million for Q1 2026 at Ligand Pharmaceuticals, down from $36.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $69.3 million in Q3 2025 to a low of -$60.3 million in Q2 2023.
• The 5-year median for Net Cash Flow is $3.1 million (2023), against an average of $5.6 million.
• Across the five-year window, Net Cash Flow soared 1146.58% in 2022 and tumbled 637.71% in 2023, its largest moves.
• Ligand Pharmaceuticals' Net Cash Flow stood at $40.9 million in 2022, then sank by 92.43% to $3.1 million in 2023, then surged by 230.62% to $10.2 million in 2024, then surged by 253.08% to $36.1 million in 2025, then slumped by 265.43% to -$59.8 million in 2026.
• The last three Net Cash Flow figures came in at -$59.8 million (Q1 2026), $36.1 million (Q4 2025), and $69.3 million (Q3 2025), per Business Quant data.